Evaluation of Curcumin and Dimethyl Chalcone in Neuropathic Pain Management Insights from In-Vivo Chronic Constriction Injury Model and Histological Analysis.

The transient receptor potential ankyrin 1 (TRPA1) receptor plays a pivotal role in various physiological processes, notably in the sensory transduction of pain and inflammation. By responding to a myriad of stimuli, including environmental irritants and endogenous inflammatory mediators, TRPA1 influences the sensation of pain. This receptors activation is crucial in pathophysiological conditions such as asthma, arthritis, and neuropathic pain, where heightened TRPA1 sensitivity often correlates with increased symptom severity. Recent research highlights the potential of targeting TRPA1 in therapeutic applications, offering a promising avenue for alleviating chronic pain and inflammatory disorders. Pharmacological agents designed to modulate TRPA1 activity could provide innovative treatment options, bridging the gap between traditional pain management and modern medicine. As scientists continue to unravel TRPA1s multifaceted roles, a clearer understanding of its mechanisms could lead to the development of more effective and safer therapies, ultimately enhancing patient care in various health contexts. This study explores the interactions of (E)-3-(4-(dimethylamino)phenyl)-1-(2,4-dimethylphenyl)prop-2-en-1-one, curcumin, and its metabolites with the TRPA1 receptor, highlighting their potential as therapeutic agents for the treatment of neuropathic pain